drugset / Trial / NCT06914011

Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06914011

Phase 3 Not yet recruiting 172 enrolled Asan Medical Center
RandomizedParallel-groupOpen-labelSupportive care

Summary

This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.

Timeline

Start
2026-05-06
Primary completion
2031-06-28
Completion
2034-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 2 unknown Intravenous
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Paclitaxel Small molecule 50 mg/m2 Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Subject Tislelizumab Monoclonal antibody 400 mg Intravenous

Indications